<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623476</url>
  </required_header>
  <id_info>
    <org_study_id>112/20</org_study_id>
    <nct_id>NCT04623476</nct_id>
  </id_info>
  <brief_title>PAtophysiological, Nodal-based Approach for Crohn's Disease Excision</brief_title>
  <acronym>PANACEAPILOT</acronym>
  <official_title>PAtophysiological, Nodal-based Approach for Crohn's Disease Excision: A PILOT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rome Tor Vergata</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single centre prospective pilot study on surgery for Crohn's disease (CD). CD universally&#xD;
      recurs after surgery and no technique so far has been proven to reduce recurrence.&#xD;
&#xD;
      The investigators speculate that a different surgical technique, based on pathophysiology of&#xD;
      the disease may prove successful in reducing rates of recurrence.&#xD;
&#xD;
      Consecutive CD patients with a surgical indication for ileocolic disease will receive an&#xD;
      extended procedure including a lymphadenectomy (Pathophysiologic excision for Crohn's&#xD;
      disease).&#xD;
&#xD;
      Primary outcome will be endoscopic recurrence rates at 6 and 12 months from surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of endoscopic CD recurrence</measure>
    <time_frame>6 months</time_frame>
    <description>Endoscopic Rutgeerts score &gt;1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of endoscopic CD recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Endoscopic Rutgeerts score &gt;1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of overall postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>Clavien Dindo I-V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>Clavien Dindo III-V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and Disease specific Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Inflammatory Bowel Disease Questionnaire (32 to 224 with higher scores representing better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and Disease specific Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Inflammatory Bowel Disease-Control (Q 1-3 with higher scores representing better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and Disease specific Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Cleveland Global Quality of Life score (0-1 with with higher scores representing better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and Disease specific Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Inflammatory Bowel Disease Questionnaire (32 to 224 with higher scores representing better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and Disease specific Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Inflammatory Bowel Disease-Control Q1-3 (0-18 with higher scores representing better quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and Disease specific Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Cleveland Global Quality of Life score (0-1 with higher scores representing better quality of life)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Crohn's Ileocolitis</condition>
  <arm_group>
    <arm_group_label>Pathophysiological Excision for Chron's disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consecutive patients (&gt;18 years old) with a surgical indication for ileocolic Crohn's disease, at their first operation for CD</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pathophysiological Excision for Crohn's disease</intervention_name>
    <description>Pathophysiological excision for Crohn's (PEC) requires a medio-lateral approach and a high vascular tie, which enables excision of lymph nodes draining the disease bowel. This procedure should not alter length of bowel resection and no additional risks are foreseen. A latero-lateral anastomosis will be fashioned following current guidelines.</description>
    <arm_group_label>Pathophysiological Excision for Chron's disease</arm_group_label>
    <other_name>PEC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All consecutive patients undergoing surgery for ileocaecal/ileocolic CD in the&#xD;
             Minimally Invasive Unit at Policlinico Tor Vergata are eligible to be enrolled.&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Crohn's Disease with a different localisation&#xD;
&#xD;
          -  Recurrent disease&#xD;
&#xD;
          -  Extensive jejunitis&#xD;
&#xD;
          -  &lt;18 years of age&#xD;
&#xD;
          -  Cancer as primary indication for surgery&#xD;
&#xD;
          -  Followed by gastroenterologists outside our centre, due to loss of follow up&#xD;
&#xD;
          -  Ileostomy. If a patient undergoes ileostomy fashioning he will be excluded from the&#xD;
             study and this will be reported&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe S Sica, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit√† di Roma Tor Vergata</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Sensi, MD</last_name>
    <phone>3385352902</phone>
    <email>brunosensi@outlook.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe S Sica, MD, PhD</last_name>
    <phone>3385333659</phone>
    <email>sigisica@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Sensi, MD</last_name>
      <phone>3385352902</phone>
      <email>brunosensi@outlook.it</email>
    </contact>
    <contact_backup>
      <last_name>Giuseppe S Sica, MD, PhD</last_name>
      <phone>3385333659</phone>
      <email>sigisica@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rome Tor Vergata</investigator_affiliation>
    <investigator_full_name>Giuseppe Sigismondo Sica</investigator_full_name>
    <investigator_title>Associate Professor, Head of Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

